Natixis’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-546,593
Closed -$3.92M 1266
2025
Q4
$3.92M Buy
546,593
+546,536
+958,835% +$4.32M 0.01% 509
2025
Q3
$609 Buy
+57
New +$559 ﹤0.01% 1034
2024
Q2
Sell
-1
Closed -$19 1107
2024
Q1
$19 Hold
1
﹤0.01% 990
2023
Q4
$14 Sell
1
-13,106
-100% -$178K ﹤0.01% 1020
2023
Q3
$228K Buy
+13,107
New +$273K ﹤0.01% 700
2023
Q1
Sell
-17,941
Closed -$501K 1137
2022
Q4
$501K Buy
17,941
+752
+4% +$19.2K ﹤0.01% 716
2022
Q3
$403K Buy
17,189
+6,155
+56% +$186K ﹤0.01% 919
2022
Q2
$372K Buy
+11,034
New +$386K ﹤0.01% 973
2021
Q3
Sell
-152,171
Closed -$4.6M 1262
2021
Q2
$4.6M Buy
+152,171
New +$5.01M 0.02% 400

Other funds holding OGN

Natixis's OGN Position: Q1 2026 in Review

Natixis sold out of Organon & Co (OGN) in Q1 2026, closing a stake of 546,593 shares — an estimated $3.92M sold.

Natixis first reported a position in OGN in Q2 2021 and held it in 9 quarters. The position peaked at $4.6M in Q2 2021. 603 funds tracked by Wall St. Rank hold OGN as of Q1 2026.

  • Natixis reported no remaining Organon & Co position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 546,593 Organon & Co shares in Q1 2026, an estimated $3.92M.
  • Natixis first reported a position in Organon & Co in Q2 2021 and held it in 9 quarters.
  • Natixis's Organon & Co position peaked at $4.6M in Q2 2021.
  • 603 funds tracked by Wall St. Rank held Organon & Co as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.